ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Completed · Phase 1 · Has a placebo group

Conditions studied: Non-Alcoholic Fatty Liver Disease

In brief

The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic subjects with overweight and obese and non-alcoholic fatty liver disease (NAFLD).

Key facts

Study ID
NCT05006885
Run by
Altimmune, Inc.
People needed
95
Starts
2021-09-30
Expected to finish
2022-08-17
Last updated by the study team
2023-07-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.